RxDoctor Payments Data

James Choi, MD

Family Medicine · Detroit, MINPI 1013359645

Payments from drug & device makers

$536in general payments, 2019–2025

Across 22 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$118
  • Actelion Pharmaceuticals US, Inc.$116
  • Philips North America LLC$62
  • Biohaven Pharmaceutical Holding Company Ltd.$49
  • Melinta Therapeutics, LLC$46
  • Jazz Pharmaceuticals Inc.$42
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$536 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$8,256
Medicare patients
44
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$86,983
TrulicityDulaglutide37$47,739
EliquisApixaban47$33,789
JardianceEmpagliflozin25$25,186
OzempicSemaglutide25$24,869
LinzessLinaclotide22$18,171
XareltoRivaroxaban20$13,964
Breo ElliptaFluticasone/Vilanterol23$13,951
Albuterol Sulfate HfaAlbuterol Sulfate285$10,376
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$6,153
Diclofenac Sodium70$6,010
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,747
Tresiba Flextouch U-100Insulin Degludec12$5,617
Mometasone Furoate27$4,772
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$4,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$118$100,934120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →